Literature DB >> 14770295

Human clade B serpins (ov-serpins) belong to a cohort of evolutionarily dispersed intracellular proteinase inhibitor clades that protect cells from promiscuous proteolysis.

G A Silverman1, J C Whisstock, D J Askew, S C Pak, C J Luke, S Cataltepe, J A Irving, P I Bird.   

Abstract

Serpins are unique among the various types of active site proteinase inhibitors because they covalently trap their targets by undergoing an irreversible conformational rearrangement. Members of the serpin superfamily are present in the three major domains of life (Bacteria, Archaea and Eukarya) as well as several eukaryotic viruses. The human genome encodes for at least 35 members that segregate evolutionarily into nine (A-I) distinct clades. Most of the human serpins are secreted and circulate in the bloodstream where they reside at critical checkpoints intersecting self-perpetuating proteolytic cascades such as those of the clotting, thrombolytic and complement systems. Unlike these circulating serpins, the clade B serpins (ov-serpins) lack signal peptides and reside primarily within cells. Most of the human clade B serpins inhibit serine and/or papain-like cysteine proteinases and protect cells from exogenous and endogenous proteinase-mediated injury. Moreover, as sequencing projects expand to the genomes of other species, it has become apparent that intracellular serpins belonging to distinct phylogenic clades are also present in the three major domains of life. As some of these serpins also guard cells against the deleterious effects of promiscuous proteolytic activity, we propose that this cytoprotective function, along with similarities in structure are common features of a cohort of intracellular serpin clades from a wide variety of species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14770295     DOI: 10.1007/s00018-003-3240-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  28 in total

Review 1.  Task Force 7: arrhythmias.

Authors:  Douglas P Zipes; Michael J Ackerman; N A Mark Estes; Augustus O Grant; Robert J Myerburg; George Van Hare
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

Review 2.  How to manage patients with inappropriate sinus tachycardia.

Authors:  Win K Shen
Journal:  Heart Rhythm       Date:  2005-09       Impact factor: 6.343

3.  Lone atrial fibrillation in vigorously exercising middle aged men: case-control study.

Authors:  J Karjalainen; U M Kujala; J Kaprio; S Sarna; M Viitasalo
Journal:  BMJ       Date:  1998-06-13

4.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

Review 5.  Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?

Authors:  Thomas Wichter; Thomas Matthias Paul; Lars Eckardt; Petra Gerdes; Paulus Kirchhof; Dirk Böcker; Günter Breithardt
Journal:  Herz       Date:  2005-03       Impact factor: 1.443

6.  The natural history of asymptomatic ventricular pre-excitation a long-term prospective follow-up study of 184 asymptomatic children.

Authors:  Vincenzo Santinelli; Andrea Radinovic; Francesco Manguso; Gabriele Vicedomini; Simone Gulletta; Gabriele Paglino; Patrizio Mazzone; Giuseppe Ciconte; Stefania Sacchi; Simone Sala; Carlo Pappone
Journal:  J Am Coll Cardiol       Date:  2009-01-20       Impact factor: 24.094

7.  Sensitivity and specificity of invasive and noninvasive testing for risk of sudden death in Wolff-Parkinson-White syndrome.

Authors:  A D Sharma; R Yee; G Guiraudon; G J Klein
Journal:  J Am Coll Cardiol       Date:  1987-08       Impact factor: 24.094

8.  Clinical correlates and prognostic significance of exercise-induced ventricular premature beats in the community: the Framingham Heart Study.

Authors:  Ali Morshedi-Meibodi; Jane C Evans; Daniel Levy; Martin G Larson; Ramachandran S Vasan
Journal:  Circulation       Date:  2004-05-17       Impact factor: 29.690

9.  Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death.

Authors:  F Gaita; C Giustetto; R Riccardi; L Mangiardi; A Brusca
Journal:  Am J Cardiol       Date:  1989-09-01       Impact factor: 2.778

10.  Aborted sudden death in the Wolff-Parkinson-White syndrome.

Authors:  C Timmermans; J L Smeets; L M Rodriguez; G Vrouchos; A van den Dool; H J Wellens
Journal:  Am J Cardiol       Date:  1995-09-01       Impact factor: 2.778

View more
  63 in total

1.  Enhanced anti-serpin antibody activity inhibits autoimmune inflammation in type 1 diabetes.

Authors:  Jan Czyzyk; Octavian Henegariu; Paula Preston-Hurlburt; Raman Baldzizhar; Christine Fedorchuk; Enric Esplugues; Kim Bottomly; Frans K Gorus; Kevan Herold; Richard A Flavell
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

Review 2.  Serpins flex their muscle: I. Putting the clamps on proteolysis in diverse biological systems.

Authors:  Gary A Silverman; James C Whisstock; Stephen P Bottomley; James A Huntington; Dion Kaiserman; Cliff J Luke; Stephen C Pak; Jean-Marc Reichhart; Phillip I Bird
Journal:  J Biol Chem       Date:  2010-05-24       Impact factor: 5.157

3.  Mutations in SERPINB7, encoding a member of the serine protease inhibitor superfamily, cause Nagashima-type palmoplantar keratosis.

Authors:  Akiharu Kubo; Aiko Shiohama; Takashi Sasaki; Kazuhiko Nakabayashi; Hiroshi Kawasaki; Toru Atsugi; Showbu Sato; Atsushi Shimizu; Shuji Mikami; Hideaki Tanizaki; Masaki Uchiyama; Tatsuo Maeda; Taisuke Ito; Jun-ichi Sakabe; Toshio Heike; Torayuki Okuyama; Rika Kosaki; Kenjiro Kosaki; Jun Kudoh; Kenichiro Hata; Akihiro Umezawa; Yoshiki Tokura; Akira Ishiko; Hironori Niizeki; Kenji Kabashima; Yoshihiko Mitsuhashi; Masayuki Amagai
Journal:  Am J Hum Genet       Date:  2013-10-24       Impact factor: 11.025

Review 4.  Serpins, immunity and autoimmunity: old molecules, new functions.

Authors:  Mariele Gatto; Luca Iaccarino; Anna Ghirardello; Nicola Bassi; Patrizia Pontisso; Leonardo Punzi; Yehuda Shoenfeld; Andrea Doria
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

5.  The Caenorhabditis elegans muscle specific serpin, SRP-3, neutralizes chymotrypsin-like serine peptidases.

Authors:  Stephen C Pak; Christopher Tsu; Cliff J Luke; Yuko S Askew; Gary A Silverman
Journal:  Biochemistry       Date:  2006-04-11       Impact factor: 3.162

6.  Serpin B3/B4, activated by STAT3, promote survival of squamous carcinoma cells.

Authors:  Simi T Ahmed; James E Darnell
Journal:  Biochem Biophys Res Commun       Date:  2008-12-12       Impact factor: 3.575

7.  A versatile monoclonal antibody specific to human SERPINB5.

Authors:  Sonia S Y Teoh; Hong Wang; Gail P Risbridger; James C Whisstock; Phillip I Bird
Journal:  Hybridoma (Larchmt)       Date:  2012-10

8.  Heparin enhances serpin inhibition of the cysteine protease cathepsin L.

Authors:  Wayne J Higgins; Denise M Fox; Piotr S Kowalski; Jens E Nielsen; D Margaret Worrall
Journal:  J Biol Chem       Date:  2009-12-03       Impact factor: 5.157

9.  SERPINB12 Is a Slow-Binding Inhibitor of Granzyme A and Hepsin.

Authors:  Jason Z Niehaus; Mark T Miedel; Misty Good; Allyson N Wyatt; Stephen C Pak; Gary A Silverman; Cliff J Luke
Journal:  Biochemistry       Date:  2015-11-05       Impact factor: 3.162

10.  Ixodes scapularis tick serine proteinase inhibitor (serpin) gene family; annotation and transcriptional analysis.

Authors:  Albert Mulenga; Rabuesak Khumthong; Katelyn C Chalaire
Journal:  BMC Genomics       Date:  2009-05-12       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.